27 withdrawn. 27 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Withdrawn 27 |
| Phase 2 | 6 | Withdrawn 6 |
Follow Arthritis: new trials by email Literature Review of Arthritis trials Research Report on Arthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TreatMent Of Knee osTeoarthritis wIth chONdroitin Sulfate - the OA MOTION Study Chondroitin Sulfate Sodium, Placebo - Knee Osteoarthritis | Phase 3 | Withdrawn | IBSA Institut Biochimique SA | 2023-12-01 | 2023-10-05 | |
| Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD) RPH-104, Placebo - Adult-Onset Still's Disease, AOSD | Phase 3 | Withdrawn | R-Pharm International, LLC | 2023-12-01 | 2024-11-15 | |
| MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis MabionCD20 (candidate biosimilar to rituximab), MabThera®, Rituxan® - Rheumatoid Arthritis | Phase 3 | Withdrawn | Mabion SA | 2023-08-03 | 2023-08-07 | |
| GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression Fisetin, GetHealthy-OA mind-body program, Placebo oral capsule - Knee Osteoarthritis, Obese | Phase 2 / Phase 3 | Withdrawn | Cale Andrew Jacobs, PhD | 2023-04-01 | 2023-05-01 | |
| A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine X0002 - Osteoarthritis of the Lumbar Spine, Pain, Back | Phase 3 | Withdrawn | Techfields Pharma Co. Ltd | 2023-03-30 | 2023-06-12 | |
| The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients Anti-TNF, JAK inhibitor - Rheumatoid Arthritis | Phase 3 | Withdrawn | Abu Dhabi Stem Cells Center | 2023-03-01 | 2025-10-06 | |
| Investigating RELEARN Neurofeedback as Treatment for Chronic Musculoskeletal Pain RELEARN Neurofeedback, Standard care control - Chronic Knee Pain, Chronic Pain | Phase 2 / Phase 3 | Withdrawn | Redo-Neurosystems | 2022-10-05 | 2024-02-06 | |
| Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed Resiniferatoxin, Placebo - Osteoarthritis, Knee, Osteo Arthritis Knee | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2021-04-01 | 2021-11-09 | |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis | Phase 3 | Withdrawn | Gilead Sciences | 2020-12-01 | 2021-01-11 | |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis | Phase 3 | Withdrawn | Gilead Sciences | 2020-12-01 | 2021-01-11 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee Resiniferatoxin, Placebo - Osteoarthritis, Knee, Knee Pain Chronic | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2020-12-01 | 2021-11-09 | |
| BMAC in Severe Hip or Knee Osteoarthritis Awaiting Arthroplasty Bone Mineral Aspirate Concentrate (BMAC) - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 / Phase 3 | Withdrawn | CAPRI Clinic | 2019-12-01 | 2020-05-06 | |
| A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study glucosamine sulphate 1500mg and meloxicam 15mg, Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, Placebos - Knee Osteoarthritis | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2019-01-01 | 2022-04-18 | |
| Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty Bupivacaine Liposome Injection, Indwelling femoral nerve block - Osteoarthritis, Osteoarthritis, Knee | Phase 2 / Phase 3 | Withdrawn | United States Naval Medical Center, San Diego | 2015-03-01 | 2017-03-10 | |
| Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) Ixekizumab, Placebo, Adalimumab - Spondylitis, Ankylosing | Phase 3 | Withdrawn | Eli Lilly and Company | 2014-07-01 | 2014-09-16 | |
| Ultrasound Guided vs Unguided Intra-articular Knee Injections Ultrasound machine, Unguided injection - Osteoarthritis, Inflammatory Arthritis | Phase 3 | Withdrawn | Mayo Clinic | 2014-03-01 | 2015-10-15 | |
| Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis Reumatocept (etanercept), Enbrel (etanercept) - Rheumatoid Arthritis | Phase 3 | Withdrawn | EMS | 2013-08-01 | 2021-02-24 | |
| An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) ACZ885, Canakinumab - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2013-01-01 | 2015-10-15 | |
| Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease ACZ885, Triamcinelone acetonide - Acute Gouty Arthritis | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2012-09-01 | 2017-04-20 | |
| Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic Biofreeze, Placebo - Knee Osteoarthritis | Phase 3 | Withdrawn | University of Chile | 2012-04-01 | 2014-07-10 |
Showing 20 of 27. Sign in to see all of them.
Osteoarthritis (11) · Osteoarthritis, Knee (11) · Arthritis, Rheumatoid (3) · Pain (3) · Spondylitis, Ankylosing (3) · Arthritis, Juvenile (2) · Chronic Pain (2) · Anemia, Sickle Cell (1) · Arthritis, Gouty (1) · Back Pain (1) · Depression (1) · Gout (1) · Infections (1) · Neoplasms (1)
Joint Diseases (27) · Musculoskeletal Diseases (27) · Rheumatic Diseases (22) · Pathological Conditions, Signs and Symptoms (7) · Autoimmune Diseases (6) · Connective Tissue Diseases (6) · Immune System Diseases (6) · Signs and Symptoms (6) · Skin and Connective Tissue Diseases (6) · Neurologic Manifestations (5) · Bone Diseases (4) · Osteoarthritis (4) · Spinal Diseases (4) · Spondylarthritis (4)
Adalimumab (2) · Chondroitin Sulfates (2) · Etanercept (2) · GLPG0634 (2) · canakinumab (2) · resiniferatoxin (2) · Acetaminophen (1) · Arthrocentesis (1) · Certolizumab Pegol (1) · Glucosamine (1) · Ibuprofen (1) · Infliximab (1) · Janus Kinase Inhibitors (1) · Meloxicam (1) · Rituximab (1)
Gilead Sciences (2) · Novartis Pharmaceuticals (2) · Sorrento Therapeutics, Inc. (2) · AFT Pharmaceuticals, Ltd. (1) · Abu Dhabi Stem Cells Center (1) · Atrium Innovations (1) · CAPRI Clinic (1) · Cale Andrew Jacobs, PhD (1) · EMS (1) · Eli Lilly and Company (1) · Emory University (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Eurofarma Laboratorios S.A. (1) · HaEmek Medical Center, Israel (1) · IBSA Institut Biochimique SA (1)
United States (5) · Canada (4) · Russia (2) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Mexico (1) · Netherlands (1)
Monica Luchi, MD (2) · Cale Jacobs, PhD (1) · Daniel Bunout, MD (1) · Dianne Bryant, PhD (1) · Erick M Hammerberg, MD (1) · Felipe Pinho, MD (1) · Gianina Statache, MD (1) · Jean-Pierre Raynauld, Dr (1) · John Moodie, Doctor (1) · Louis Bessette, Dr (1) · Matthew Pingree, MD (1) · Mikhail Samsonov (1)
2019 (2)